Business
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria
About this update from Equillium, Inc.
[{"type":"text","content":"\nAnnounced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease\n\nReported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab\n\nReported interim safety data from first cohort of asthma patients in Phase 1b EQUIP study\n\nCompany reaffirms guidance for EQUIP Phase 1b topline data in Q4 2021, and updates guidance to commence acute GVHD pivotal study in early 2022 and for interim data from EQUALISE Phase 1b Type B lupus nephritis patients to mid-2022\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2021, and provided an update on its clinical programs.\n\n“Following positive topline data from the EQUATE study, we started the third quarter by announcing our plans to advance itolizumab into a pivotal clinical study in first-line acute graft-versus-host disease, which we anticipate commencing early in the new year,” said Bruce Steel, chief executive officer at Equillium. “Recent strategic activity in the GVHD therapeutic segment demonstrates industry’s recognition of the high unmet medical need for effective treatments for patients suffering from this deadly disease, and we believe our pivotal study could position itolizumab to become the first approved therapy to treat patients with acute GVHD in the first-line setting. We are also encouraged by the reductions in proteinuria observed in the subgroup data from the Type A portion of the EQUALISE study in patients with systemic lupus erythematosus, without lupus nephritis, that had elevated baseline urine protein/creatinine and albumin/creatinine ratios. Based on the Type A data we amended the protocol in the Type B portion to include newly diagnosed patients in addition to refractory patients and selected the 1.6 mg/kg dose. As a result of these protocol enhancements and due to challenges in patient recruitment amid the ongoing global pandemic, we now expect to announce interim data from the Type B portion of the study in patients with lupus nephritis mid-year 2022. We look forward to initiating our pivotal study in first-line acute GVHD early in the new year a...